ArticleTherapeutic advances in medical oncology2025

Rationale and design for a phase IIIb trial of first-line tremelimumab plus durvalumab versus pembrolizumab, in combination with chemotherapy, in patients with non-squamous metastatic non-small-cell lung cancer and mutations or co-mutations in

Ferdinandos Skoulidis et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.